Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30207% above fair value
$314.32−13.61 (-4.15%)
Close on Nov 20, 2026Market cap $15.01BP/E –Yield –
Charles River Laboratories International net income
Net income is the profit left for shareholders after every expense, interest and tax.
Charles River Laboratories International's net income for the twelve months ending Jun 27, 2026 was -$238.46M. For fiscal 2025 it was -$144.34M, down 750.1% from the year before. The highest annual figure on record is $486.23M in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | -$144.34M | -750.1% |
| FY2024 | Dec 28, 2024 | $22.20M | -95.3% |
| FY2023 | Dec 30, 2023 | $474.62M | -2.4% |
| FY2022 | Dec 31, 2022 | $486.23M | +24.4% |
| FY2021 | Dec 25, 2021 | $390.98M | +7.3% |
| FY2020 | Dec 26, 2020 | $364.30M | +44.6% |
| FY2019 | Dec 28, 2019 | $252.02M | +11.3% |
| FY2018 | Dec 29, 2018 | $226.37M | +83.5% |
| FY2017 | Dec 30, 2017 | $123.36M | -20.3% |
| FY2016 | Dec 31, 2016 | $154.77M | +3.7% |
| FY2015 | Dec 26, 2015 | $149.31M | +17.8% |
| FY2014 | Dec 27, 2014 | $126.70M | +23.2% |
| FY2013 | Dec 28, 2013 | $102.83M | – |
| FY2010 | Dec 25, 2010 | -$336.67M | -394.2% |
| FY2009 | Dec 26, 2009 | $114.44M | – |
| FY2008 | Dec 27, 2008 | -$524.51M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | -$1.48M | -102.8% |
| Q1 FY2026 | Mar 28, 2026 | -$14.84M | -158.3% |
| Q4 FY2025 | Dec 27, 2025 | -$276.56M | – |
| Q3 FY2025 | Sep 27, 2025 | $54.42M | -21.9% |
| Q2 FY2025 | Jun 28, 2025 | $52.33M | -44.4% |
| Q1 FY2025 | Mar 29, 2025 | $25.47M | -65.1% |
| Q4 FY2024 | Dec 28, 2024 | -$214.50M | -214.7% |
| Q3 FY2024 | Sep 28, 2024 | $69.66M | -20.3% |
| Q2 FY2024 | Jun 29, 2024 | $94.08M | -3.0% |
| Q1 FY2024 | Mar 30, 2024 | $72.96M | -29.3% |
| Q4 FY2023 | Dec 30, 2023 | $187.08M | -0.2% |
| Q3 FY2023 | Sep 30, 2023 | $87.39M | -9.4% |
| Q2 FY2023 | Jul 1, 2023 | $97.02M | -11.3% |
| Q1 FY2023 | Apr 1, 2023 | $103.13M | +10.9% |
| Q4 FY2022 | Dec 31, 2022 | $187.41M | +36.2% |
| Q3 FY2022 | Sep 24, 2022 | $96.47M | -6.7% |
| Q2 FY2022 | Jun 25, 2022 | $109.32M | +23.6% |
| Q1 FY2022 | Mar 26, 2022 | $93.02M | +51.2% |
| Q4 FY2021 | Dec 25, 2021 | $137.58M | -3.9% |
| Q3 FY2021 | Sep 25, 2021 | $103.43M | +0.5% |
| Q2 FY2021 | Jun 26, 2021 | $88.45M | +31.2% |
| Q1 FY2021 | Mar 27, 2021 | $61.53M | +21.2% |
| Q4 FY2020 | Dec 26, 2020 | $143.19M | +78.2% |
| Q3 FY2020 | Sep 26, 2020 | $102.91M | +41.3% |
| Q2 FY2020 | Jun 27, 2020 | $67.44M | +54.2% |
| Q1 FY2020 | Mar 28, 2020 | $50.77M | -7.9% |
| Q4 FY2019 | Dec 28, 2019 | $80.35M | +34.7% |
| Q3 FY2019 | Sep 28, 2019 | $72.81M | +20.6% |
| Q2 FY2019 | Jun 29, 2019 | $43.73M | -18.6% |
| Q1 FY2019 | Mar 30, 2019 | $55.13M | +4.8% |
| Q4 FY2018 | Dec 29, 2018 | $59.67M | – |
| Q3 FY2018 | Sep 29, 2018 | $60.37M | +15.0% |
| Q2 FY2018 | Jun 30, 2018 | $53.71M | -0.5% |
| Q1 FY2018 | Mar 31, 2018 | $52.63M | +12.5% |
| Q4 FY2017 | Dec 30, 2017 | -$29.85M | -166.8% |
| Q3 FY2017 | Sep 30, 2017 | $52.47M | +39.1% |
| Q2 FY2017 | Jul 1, 2017 | $53.95M | – |
| Q1 FY2017 | Apr 1, 2017 | $46.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $44.68M | – |
| Q3 FY2016 | Sep 24, 2016 | $37.74M | – |
See a number that looks wrong?